Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase
Top Cited Papers
- 1 March 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (7), 1116-1119
- https://doi.org/10.1021/jm0204183
Abstract
To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.Keywords
This publication has 4 references indexed in Scilit:
- Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase InhibitorsJournal of Medicinal Chemistry, 2002
- VEGF: an update on biological and therapeutic aspectsCurrent Opinion in Biotechnology, 2000
- New paradigms for the treatment of cancer: The role of anti-angiogenesis agentsAdvances in Cancer Research, 2000
- Evidence for Distinct Signaling Properties and Biological Responses Induced by the PDGF Receptor α and β SubtypesGrowth Factors, 1999